评价-话题@MedSci

#评价#

750篇内容 | 3006人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1444612, encodeId=0c631444612d5, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, objectTitle=CLIN CHEM LAB MED：多中心对Alinity hq血液分析仪性能评价, objectType=article, longId=187459, objectId=a94118e45911, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a94118e45911, replyNumber=0, likeNumber=66, createdTime=2020-02-06, rootId=0, userName=huagfeg, userId=1fee5134542, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a94118e45911, moduleTitle=CLIN CHEM LAB MED：多中心对Alinity hq血液分析仪性能评价, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a94118e45911)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1444611, encodeId=89ff144461128, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, objectTitle=Alnylam的RNA干扰药物Givlaari作为欧盟首例治疗急性肝卟啉症的药物，获得了CHMP的积极评价, objectType=article, longId=187288, objectId=72c718e28817, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=72c718e28817, replyNumber=0, likeNumber=80, createdTime=2020-02-04, rootId=0, userName=huagfeg, userId=1fee5134542, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=72c718e28817, moduleTitle=Alnylam的RNA干扰药物Givlaari作为欧盟首例治疗急性肝卟啉症的药物，获得了CHMP的积极评价, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=72c718e28817)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1444610, encodeId=d98b1444610f8, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, objectTitle=对于未经治疗的慢性淋巴细胞白血病患者，AbbVie的BCL-2抑制剂VENCLYXTO联合CD20单抗获得欧洲人用药物委员会的正面评价, objectType=article, longId=187245, objectId=3b7518e245e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3b7518e245e4, replyNumber=0, likeNumber=56, createdTime=2020-02-04, rootId=0, userName=huagfeg, userId=1fee5134542, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3b7518e245e4, moduleTitle=对于未经治疗的慢性淋巴细胞白血病患者，AbbVie的BCL-2抑制剂VENCLYXTO联合CD20单抗获得欧洲人用药物委员会的正面评价, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3b7518e245e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1444609, encodeId=101b14446098c, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, objectTitle=Emergent BioSolutions的口服霍乱疫苗Vaxchora，获得欧洲人用药品委员会（CHMP）的正面评价，有望近期获批, objectType=article, longId=187235, objectId=c21b18e23540, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c21b18e23540, replyNumber=0, likeNumber=88, createdTime=2020-02-04, rootId=0, userName=huagfeg, userId=1fee5134542, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c21b18e23540, moduleTitle=Emergent BioSolutions的口服霍乱疫苗Vaxchora，获得欧洲人用药品委员会（CHMP）的正面评价，有望近期获批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c21b18e23540)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1444608, encodeId=7c88144460852, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, objectTitle=辉瑞的美罗华仿制药RUXIENCE的营销申请，获得欧盟人用药物委员会的积极评价, objectType=article, longId=187232, objectId=b01918e23299, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b01918e23299, replyNumber=0, likeNumber=63, createdTime=2020-02-04, rootId=0, userName=huagfeg, userId=1fee5134542, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b01918e23299, moduleTitle=辉瑞的美罗华仿制药RUXIENCE的营销申请，获得欧盟人用药物委员会的积极评价, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b01918e23299)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1444607, encodeId=509a144460e0f, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, objectTitle=上合组织高度评价中国抗击新型冠状病毒感染肺炎疫情努力, objectType=article, longId=187150, objectId=232b18e15067, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=232b18e15067, replyNumber=0, likeNumber=61, createdTime=2020-02-03, rootId=0, userName=huagfeg, userId=1fee5134542, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=232b18e15067, moduleTitle=上合组织高度评价中国抗击新型冠状病毒感染肺炎疫情努力, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=232b18e15067)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1444606, encodeId=4a711444606f0, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, objectTitle=Br J Anaesth：地塞米松对成人扁桃体切除术后疼痛与镇痛药物影响的系统评价, objectType=article, longId=186917, objectId=c5e418691e63, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c5e418691e63, replyNumber=0, likeNumber=78, createdTime=2020-01-30, rootId=0, userName=huagfeg, userId=1fee5134542, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c5e418691e63, moduleTitle=Br J Anaesth：地塞米松对成人扁桃体切除术后疼痛与镇痛药物影响的系统评价, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c5e418691e63)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1444605, encodeId=00f81444605aa, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, objectTitle=哈医大二院于波等：颈脉斑块指标能否评价冠脉斑块特征？, objectType=article, longId=186044, objectId=444418604486, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=444418604486, replyNumber=0, likeNumber=69, createdTime=2020-01-12, rootId=0, userName=huagfeg, userId=1fee5134542, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=444418604486, moduleTitle=哈医大二院于波等：颈脉斑块指标能否评价冠脉斑块特征？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=444418604486)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1444604, encodeId=a89114446044e, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, objectTitle=Clin Chem：高敏感性肌钙蛋白I的诊断评价如何？, objectType=article, longId=185628, objectId=a7be1856281f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a7be1856281f, replyNumber=0, likeNumber=70, createdTime=2020-01-04, rootId=0, userName=huagfeg, userId=1fee5134542, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a7be1856281f, moduleTitle=Clin Chem：高敏感性肌钙蛋白I的诊断评价如何？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a7be1856281f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1444603, encodeId=806414446037f, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, objectTitle=【NMPA】公开征求《真实世界数据用于医疗器械临床评价技术指导原则》意见, objectType=article, longId=185449, objectId=85f918544935, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=85f918544935, replyNumber=0, likeNumber=67, createdTime=2020-01-01, rootId=0, userName=huagfeg, userId=1fee5134542, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=85f918544935, moduleTitle=【NMPA】公开征求《真实世界数据用于医疗器械临床评价技术指导原则》意见, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=85f918544935)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1444602, encodeId=669b144460299, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, objectTitle=2019年一致性评价药品梳理, objectType=article, longId=185301, objectId=d6ae18530100, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d6ae18530100, replyNumber=0, likeNumber=73, createdTime=2019-12-28, rootId=0, userName=huagfeg, userId=1fee5134542, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d6ae18530100, moduleTitle=2019年一致性评价药品梳理, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d6ae18530100)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1444601, encodeId=cceb1444601b0, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, objectTitle=重磅！疫苗“一致性评价”来了, objectType=article, longId=185205, objectId=092f185205dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=092f185205dd, replyNumber=0, likeNumber=61, createdTime=2019-12-26, rootId=0, userName=huagfeg, userId=1fee5134542, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=092f185205dd, moduleTitle=重磅！疫苗“一致性评价”来了, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=092f185205dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1444600, encodeId=491f144460000, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, objectTitle=Clinica Chimica Acta：MALDI-TOF质谱测定糖化血红蛋白的评价, objectType=article, longId=184068, objectId=8836184068ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8836184068ed, replyNumber=0, likeNumber=60, createdTime=2019-12-04, rootId=0, userName=huagfeg, userId=1fee5134542, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8836184068ed, moduleTitle=Clinica Chimica Acta：MALDI-TOF质谱测定糖化血红蛋白的评价, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8836184068ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1444599, encodeId=6fd314445991f, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, objectTitle=Clinica Chimica Acta：自动间接免疫荧光法检测抗dsDNA抗体的评价, objectType=article, longId=184067, objectId=f66d18406e70, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f66d18406e70, replyNumber=0, likeNumber=55, createdTime=2019-12-04, rootId=0, userName=huagfeg, userId=1fee5134542, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f66d18406e70, moduleTitle=Clinica Chimica Acta：自动间接免疫荧光法检测抗dsDNA抗体的评价, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f66d18406e70)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1444598, encodeId=d5541444598fa, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, objectTitle=官方：仿制药一致性评价工作进入常态已审评通过123个品种, objectType=article, longId=183731, objectId=1fbf183e316b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1fbf183e316b, replyNumber=0, likeNumber=59, createdTime=2019-11-30, rootId=0, userName=huagfeg, userId=1fee5134542, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1fbf183e316b, moduleTitle=官方：仿制药一致性评价工作进入常态已审评通过123个品种, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1fbf183e316b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1444597, encodeId=2f20144459e1b, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, objectTitle=注射剂一致性评价的，这点很重要, objectType=article, longId=183655, objectId=a6e5183655e5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a6e5183655e5, replyNumber=0, likeNumber=68, createdTime=2019-11-28, rootId=0, userName=huagfeg, userId=1fee5134542, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a6e5183655e5, moduleTitle=注射剂一致性评价的，这点很重要, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a6e5183655e5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1444596, encodeId=350d14445960a, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, objectTitle=CLIN CHEM LAB MED：一种新的流式细胞术方法在常规血液学工作流程中的初步评价, objectType=article, longId=183138, objectId=27a5183138a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=27a5183138a7, replyNumber=0, likeNumber=74, createdTime=2019-11-19, rootId=0, userName=huagfeg, userId=1fee5134542, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=27a5183138a7, moduleTitle=CLIN CHEM LAB MED：一种新的流式细胞术方法在常规血液学工作流程中的初步评价, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=27a5183138a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1444595, encodeId=f70214445952f, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, objectTitle=Hypertension：评价高血压心脏受损，可用4期法，右心受累预后最差！, objectType=article, longId=182682, objectId=c575182682c0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c575182682c0, replyNumber=0, likeNumber=129, createdTime=2019-11-10, rootId=0, userName=huagfeg, userId=1fee5134542, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c575182682c0, moduleTitle=Hypertension：评价高血压心脏受损，可用4期法，右心受累预后最差！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c575182682c0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1444594, encodeId=9b1e1444594ab, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, objectTitle=恒瑞医药来曲唑片通过仿制药一致性评价, objectType=article, longId=182568, objectId=721418256882, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=721418256882, replyNumber=0, likeNumber=66, createdTime=2019-11-09, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=721418256882, moduleTitle=恒瑞医药来曲唑片通过仿制药一致性评价, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=721418256882)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1444593, encodeId=92bc1444593de, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, objectTitle=CDE发布特殊注射剂质量和疗效一致性评价技术要求（征求意见稿）, objectType=article, longId=182524, objectId=c111182524c9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c111182524c9, replyNumber=0, likeNumber=89, createdTime=2019-11-08, rootId=0, userName=huagfeg, userId=1fee5134542, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c111182524c9, moduleTitle=CDE发布特殊注射剂质量和疗效一致性评价技术要求（征求意见稿）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c111182524c9)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

评价

2020-05-29

huagfeg (审核中...)

前往app查看评论内容

#评价#

CLIN CHEM LAB MED：多中心对Alinity hq血液分析仪性能评价

2020-02-06

huagfeg (审核中...)

前往app查看评论内容

#评价#

Alnylam的RNA干扰药物Givlaari作为欧盟首例治疗急性肝卟啉症的药物，获得了CHMP的积极评价

2020-02-04

huagfeg (审核中...)

前往app查看评论内容

#评价#

对于未经治疗的慢性淋巴细胞白血病患者，AbbVie的BCL-2抑制剂VENCLYXTO联合CD20单抗获得欧洲人用药物委员会的正面评价

2020-02-04

huagfeg (审核中...)

前往app查看评论内容

#评价#

Emergent BioSolutions的口服霍乱疫苗Vaxchora，获得欧洲人用药品委员会（CHMP）的正面评价，有望近期获批

2020-02-04

huagfeg (审核中...)

前往app查看评论内容

#评价#

辉瑞的美罗华仿制药RUXIENCE的营销申请，获得欧盟人用药物委员会的积极评价

2020-02-04

huagfeg (审核中...)

前往app查看评论内容

#评价#

上合组织高度评价中国抗击新型冠状病毒感染肺炎疫情努力

2020-02-03

huagfeg (审核中...)

前往app查看评论内容

#评价#

Br J Anaesth：地塞米松对成人扁桃体切除术后疼痛与镇痛药物影响的系统评价

2020-01-30

huagfeg (审核中...)

前往app查看评论内容

#评价#

哈医大二院于波等：颈脉斑块指标能否评价冠脉斑块特征？

2020-01-12

huagfeg (审核中...)

前往app查看评论内容

#评价#

Clin Chem：高敏感性肌钙蛋白I的诊断评价如何？

2020-01-04

huagfeg (审核中...)

前往app查看评论内容

#评价#

【NMPA】公开征求《真实世界数据用于医疗器械临床评价技术指导原则》意见

2020-01-01

huagfeg (审核中...)

前往app查看评论内容

#评价#

2019年一致性评价药品梳理

2019-12-28

huagfeg (审核中...)

前往app查看评论内容

#评价#

重磅！疫苗“一致性评价”来了

2019-12-26

huagfeg (审核中...)

前往app查看评论内容

#评价#

Clinica Chimica Acta：MALDI-TOF质谱测定糖化血红蛋白的评价

2019-12-04

huagfeg (审核中...)

前往app查看评论内容

#评价#

Clinica Chimica Acta：自动间接免疫荧光法检测抗dsDNA抗体的评价

2019-12-04

huagfeg (审核中...)

前往app查看评论内容

#评价#

官方：仿制药一致性评价工作进入常态已审评通过123个品种

2019-11-30

huagfeg (审核中...)

前往app查看评论内容

#评价#

注射剂一致性评价的，这点很重要

2019-11-28

huagfeg (审核中...)

前往app查看评论内容

#评价#

CLIN CHEM LAB MED：一种新的流式细胞术方法在常规血液学工作流程中的初步评价

2019-11-19

huagfeg (审核中...)

前往app查看评论内容

#评价#

Hypertension：评价高血压心脏受损，可用4期法，右心受累预后最差！

2019-11-10

智智灵药 (审核中...)

前往app查看评论内容

#评价#

恒瑞医药来曲唑片通过仿制药一致性评价

2019-11-09

huagfeg (审核中...)

前往app查看评论内容

#评价#

CDE发布特殊注射剂质量和疗效一致性评价技术要求（征求意见稿）

2019-11-08

科室
- - 订阅+
  - 更多科室
工具
服务